

Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c⁺/CD8 α ⁺ dendritic cells

Masahiro Azuma, Takashi Ebihara,[†] Hiroyuki Oshiumi, Misako Matsumoto and Tsukasa Seya*

Department of Microbiology and Immunology; Hokkaido University Graduate School of Medicine; Sapporo, Japan

[†]Current affiliation: Howard Hughes Medical Institute; Washington University School of Medicine; St. Louis, MO USA

Keywords: cross-presentation, dendritic cell, TLR3, TICAM-1 (TRIF), tumoricidal CTL

Abbreviations: APC, antigen-presenting cells; CTL, cytotoxic T lymphocytes; DAMP, damage-associated molecular pattern; DC, dendritic cells; IFN, interferon; IPS-1, IFN β promoter stimulator-1; MDA5, melanoma differentiation associated gene 5; Mf, macrophages; NK, natural killer; OVA, ovalbumin; PAMP, pathogen-associated molecular pattern; PRR, pattern-recognition receptors; PV, poliovirus; RIG-I, retinoic acid inducible gene-1; SL8, an OVA tetramer; TICAM-1, Toll-IL-1 receptor homology domain-containing molecule-1; TLR, Toll-like receptor; WT, wild-type

PolyI:C is a nucleotide pattern molecule that induces cross-presentation of foreign Ag in myeloid dendritic cells (DC) and MHC Class I-dependent proliferation of cytotoxic T lymphocytes (CTL). DC (BM or spleen CD8 α ⁺) have sensors for dsRNA including polyI:C to signal facilitating cross-presentation. Endosomal TLR3 and cytoplasmic RIG-I/MDA5 are reportedly responsible for polyI:C sensing and presumed to deliver signal for cross-presentation via TICAM-1 (TRIF) and IPS-1 (MAVS, Cardif, VISA) adaptors, respectively. In fact, when tumor-associated Ag (TAA) was simultaneously taken up with polyI:C in DC, the DC cross-primed CTL specific to the TAA in a syngenic mouse model. Here we tested which of the TICAM-1 or IPS-1 pathway participate in cross-presentation of tumor-associated soluble Ag and retardation of tumor growth in the setting with a syngeneic tumor implant system, EG7/C57BL6, and exogenously challenged soluble Ag (EG7 lysate) and polyI:C. When EG7 lysate and polyI:C were subcutaneously injected in tumor-bearing mice, EG7 tumor growth retardation was observed in wild-type and to a lesser extent IPS-1^{-/-} mice, but not TICAM-1^{-/-} mice. IRF-3/7 were essential but IPS-1 and type I IFN were minimally involved in the polyI:C-mediated CTL proliferation. Although both TICAM-1 and IPS-1 contributed to CD86/CD40 upregulation in CD8 α ⁺ DC, H2K^b-SL8 tetramer and OT-1 proliferation assays indicated that OVA-recognizing CD8 T cells predominantly proliferated in vivo through TICAM-1 and CD8 α ⁺ DC is crucial in ex vivo analysis. Ultimately, tumor regresses > 8 d post polyI:C administration. The results infer that soluble tumor Ag induces tumor growth retardation, i.e., therapeutic potential, if the TICAM-1 signal coincidentally occurs in CD8 α ⁺ DC around the tumor.

Introduction

Cytotoxic T lymphocytes (CTL) and natural killer (NK) cells are two major effectors for antitumor cellular immunity. These effectors are driven through activation of dendritic cells (DC) and/or macrophages (Mf), which is mediated by pattern-recognition receptors (PRRs) for the recognition of microbial patterns.^{1,2} Antigen (Ag) presentation and upregulation of NK cell-activating ligands are major events induced in DC/Mf in response to PRRs, which link to evoking CTL- and NK-antitumor immunity, respectively. The immune-potentiating function of specific components of the classical adjuvants are largely attributable to the ligand activity of PRRs (CpG DNA/TLR9, polyI:C/TLR3, monophosphoryl lipid (MPL) A/TLR4, Pam2/TLR2, etc.).³ That

is, the DC/Mf competent to drive effectors are generated through PRR signal in inflammatory nest where affected cells and recruited immune cells encounter exogenous or endogenous PRR ligands. Since studying the functional properties of PRRs in tumor immunity is on the way using a variety of possible ligands and cell biological analyses, immune responses reflecting the total adjuvant potential around Ag-presenting cells (APC) in local inflammatory nests are not always elucidated even in mice.

RNA-sensing PRR pathways, including TLR3-TICAM-1, TLR7-MyD88 and RIG-I/MDA5-IPS-1 participate in driving Type I IFN induction and cellular immunity in DC subsets.^{1,4,5} Type I IFN and the IFNAR pathway in DC and other cells reportedly evoke and amplify T cell immunity.^{5,6} TLR7 resides exclusively in plasmacytoid DC⁷ whereas TLR3 mainly exists in

*Correspondence to: Tsukasa Seya; Email: seya-tu@pop.med.hokudai.ac.jp

Submitted: 02/04/12; Revised: 03/02/12; Accepted: 03/02/12

<http://dx.doi.org/10.4161/onci.19893>

myeloid DC/Mf and epithelial cells.⁸ They are localized on the membrane of the endosome and deliver the signal via their adaptors, MyD88 and TICAM-1.^{7,8} RIG-I and MDA5 are ubiquitously distributed to a variety of mouse cells and signal the presence of cytoplasmic viral products through IPS-1.⁹ Thus, TLR3 and RIG-I/MDA5 are candidates associated with DC maturation to drive effector cells.¹⁰ Indeed, viral dsRNA analog, polyI:C, is a representative ligand for TLR3 and MDA5 and induces polyI:C-mediated DC-NK reciprocal activation.^{11,12} These are also true in human DC.¹³

The point of this study is by which pathway antitumor CTL are induced for tumor regression in a mouse tumor-implant model. It has been postulated that DC present exogenous tumor Ag to the MHC Class I-restricted Ag-presentation pathway and proliferate CD8 T cells specific to the extrinsic Ag. When tumor cells provide soluble and insoluble exogenous Ag, this Class I Ag presentation occurs mostly TAP/proteasome-dependent, suggesting the pathway partly sharing with that for endogenous Ag presentation. This DC's ability to deliver exogenous Ag to the pathway for MHC Class I-restricted Ag presentation has been described as cross-presentation.¹⁴ DC cross-presentation leads to the cross-priming and proliferation of Ag-specific CD8 T cells in vivo and in vitro.¹⁴⁻¹⁸ A variety of PAMP^{15,16} and intrinsic DAMP¹⁷ as well as other factors including Type I IFN,^{5,18} CD4⁺ T cells¹⁹ and NKT cells²⁰ augment cross-priming in tumor-bearing mice. However, by what molecular mechanism polyI:C enhances CTL induction in tumor-bearing mice remains largely unsettled.

Here, we made an EG7 tumor-implant mouse system and treated the mice with s.c.-injected ovalbumin (OVA)-containing cell lysates (Ag) and polyI:C. Spleen CD8 α ⁺ DC turn CTL-inducible when stimulated with Ag and polyI:C. In either case of s.c., i.p., or i.v. injection of polyI:C, the TLR3/TICAM-1 pathway predominantly participates in CD8 α ⁺ DC cross-priming and antitumor CTL induction. Earlier studies using non-tumor models, suggested that both TLR3 and MDA5 appeared to participate in polyI:C-dependent CTL induction.²¹ TLR3 is predominantly involved in primary Ag response and Th1 skewing,²² while MDA5 participates in secondary Ag response.²³ Importance of TLR3 in induction of cross-priming was first suggested by Schulz et al., who used OVA/polyI:C-loaded or virus-infected xenogenic (Vero) cells and mouse DC.¹⁶ Here we demonstrate that the antitumor polyI:C activity is sustained by the TICAM-1 pathway in any route of injection in tumor-implant mice: antitumor CTL responses are mostly abrogated in TICAM-1^{-/-} but not IPS-1^{-/-} mice.

Results

Properties of EG7 tumor with high MHC in tumor-loading mice. The properties of the EG7 line we used are consistent with those reported previously.^{24,25} It expressed high MHC Class I (H2-Kb) and no Qa-1b or Rae-1 (Fig. S1). The expression levels of these proteins were barely changed before and after implantation of EG7 cells into mice. Cell viability was not affected by in vitro stimulation with polyI:C only (Fig. S1B).

However, a batch-to-batch difference of cell viability may have affected the rate of tumor growth in each mouse tumor-implant experiment.

CD8⁺ T cells are responsible for tumor retardation by polyI:C. EG7 cells (2×10^6) were inoculated into the back of C57BL/6 (WT), and the indicated reagents were subcutaneously (s.c.) injected around the EG7 tumor (Fig. 1A). Growth retardation of tumor was observed by treatment with polyI:C or polyI:C plus EG7 lysate (Fig. 1A). EG7 lysate only had no effect on tumor regression. When CD8 β ⁺ T cells were depleted before EG7 lysate/polyI:C treatment, polyI:C-mediated tumor growth suppression was cancelled (Fig. 1A), suggesting the participation of CD8 T cells in tumor growth suppression. The therapeutic potential of polyI:C appeared to be more reproducible in the presence of EG7 lysate than in the absence, judged from the increases of activated CD8⁺ T cells (Fig. 1B) and cytotoxic activity (Fig. 1C) of LN T cells isolated from the mice sacrificed after the last therapy. Yet, the EG7 Ag could be more or less supplied from the implant tumor. NK1.1⁺ cells did not participate in this EG7 tumor regression in this setting (data not shown).

Since EG7 lysate contains OVA, OVA-specific T cells in draining LN and spleen of the WT mice were counted by tetramer assay after the last therapy (Fig. S2A and B). The numbers of tetramer-positive cells were prominently increased in LN and spleen in mice with EG7 lysate and polyI:C. We confirmed the importance of simultaneous administration of Ag plus polyI:C for OVA-specific CTL induction as in Figure S2C, where pure Ag (OVA) was used instead of EG7 lysate for immunotherapy. The polyI:C adjuvant function appeared to be more efficient in the mixture of pure Ag than in polyI:C alone. Tumor regression (Fig. S2C) and OVA-specific CTL induction (Fig. S2D) were clearly observed in this additional experiment. To obtain reproducible data, we employed the EG7 lysate/polyI:C combination therapy as follows.

IFN-inducing pathways are involved in PolyI:C-derived EG7 growth retardation. We next inoculated EG7 cells (2×10^6) into the back of C57BL/6 (WT), TICAM-1^{-/-}, IPS-1^{-/-}, or TICAM-1/IPS-1 double-deficient (DKO) mice (Fig. 2). We s.c. administered EG7 lysate with or without polyI:C around the tumor. The EG7 lysate was the soluble fraction of EG7 which removed insoluble debris by centrifugation. The EG7 lysate contained unprecipitated micro-debris and soluble Ag. No other emulsified reagent was added for immunization. Thus, the adjuvant function of polyI:C per se is reflected in the tumor growth, although polyI:C had to be injected into mice twice a week. Retardation of tumor growth was observed > 8 d after immunization with EG7 lysate + polyI:C in WT mice, though no growth retardation without polyI:C (Fig. 2A). The polyI:C-mediated tumor growth suppression was largely abrogated in TICAM-1^{-/-} (Fig. 2B) and to a lesser extent in IPS-1^{-/-} mice (Fig. 2C), and completely in TICAM-1/IPS-1 DKO mice (Fig. 2D). Hence, TICAM-1 plays an important role in inducing polyI:C-mediated tumor growth retardation in the s.c. setting we employed.

CD8 T cell activation induced by the TICAM-1 pathway. CD8 T cell activation in the inguinal LN was tested with polyI:C + EG7 lysate in EG7 tumor-bearing mice using CD69 as




Figure 1. PolyI:C induces CTL-mediated tumor regression. (A) WT mice were challenged with EG7 cells and were treated with PBS (●), EG7 lysates (▲), polyI:C (◆) and EG7 lysates + polyI:C (■). The adjuvant therapy was started at the time indicated by the arrow and the indicated reagents injected twice per week. One of the two PBS groups (○) and one of the two EG7 lysates + polyI:C groups (◻) were treated with anti-CD8 β ascites in order to deplete CD8⁺ T cells once a week. Each group had 3–5 mice. (B) Draining inguinal LNs were harvested 24 h after the last treatment and the proportion of CD69-expressing CD8⁺ cells were counted. (C) LN cells were co-cultured with MMC-treated EG7 cells for 3 d and subjected to ⁵¹Cr release assay to evaluate CTL activity. E/T = 50. All error bars used in this figure show \pm SEM. Data are representative of two independent experiments. One-way analysis of variance (ANOVA) with Bonferroni's test was performed to analyze statistical significance. **, $p < 0.01$.

an activating marker. Twenty-four hours after the last polyI:C + EG7 sec.c. treatment, cells were harvested from the LN excised (Fig. 3A). FACS profiles of total cells from each mouse group are shown in Fig. S3. By combination therapy with EG7 lysate and polyI:C, T cells were activated in WT and IPS-1^{-/-} mice, but the proportion of CD8 T cells was not affected by the therapy (Fig. S4A). Under the same conditions, T cells were barely activated in TICAM-1^{-/-} mice in response to polyI:C (Fig. 3A). The proportion of CD69⁺ cells are indicated in Figure 3B. IL-2 (Fig. 3C) and IFN γ (Fig. S4B) were highly induced in the

presentation induced by polyI:C mostly depends on the TLR3-TICAM-1 pathway followed by transcriptional regulation by IRF-3/7 in any administration route, and is further promoted by Type I IFN presumably produced by the stromal cells through the IPS-1 pathway.²⁶

IPS-1 induces DC maturation but not cross-priming in vivo. Spleen DC maturation by i.v.-injected polyI:C was tested ex vivo using CD8 α^+ DC and CD8 α^- DC isolated from WT or KO mice with no tumor as indicated in Figure 5A. The maturation markers CD86 and CD40 were upregulated on both CD8 α^+ and CD8 α^-

WT and IPS-1^{-/-} LN cells, while they were not induced in TICAM-1^{-/-} or DKO cells. IFN γ levels were upregulated only in polyI:C-treated tumor-bearing mice, although the WT > IPS-1^{-/-} profile for IFN γ production was reproducibly observed (Fig. S4B).

In vivo proliferation of CD8 T cells judged by tetramer assay and IFN γ induction. We next tested whether i.p. injection of polyI:C plus OVA induces CTL proliferation. PolyI:C and OVA were i.p. injected into mice and the polyI:C-dependent cross-priming of CD8 T cells were examined using the OVA tetramer assay. OVA-specific CD8 T cells were clonally proliferated in WT and IPS-1^{-/-} mice, but not in TICAM-1/IPS-1 DKO and IRF-3/7^{-/-} mice (Fig. 4A). Proliferation of OVA-specific CD8 T cells were severely suppressed in TICAM-1^{-/-} mice (Fig. 4A), suggesting that polyI:C-mediated cross-priming of CD8 T cells largely depends on the TICAM-1 pathway followed by IRF-3/7 activation in the i.p. route. The results were reproduced in additional experiments using more mice (Fig. 4B) and TLR3^{-/-} mice (Fig. S5A and B). The polyI:C cytokine response, where IFN α is IPS-1-dependent while IL-12p40 is TICAM-1-dependent, was also confirmed in serum level by polyI:C i.p. injection (Fig. S5E). Specific induction of IFN γ (Fig. 4C) was also observed in parallel with the results of Figure 4A.

Whether or not i.v. injection of polyI:C plus OVA induces Ag-specific CTL and cytotoxicity was next checked. OVA-specific OT-1 proliferation and cytotoxicity (Fig. 4D and E) were observed in in vivo analyses of WT and IPS-1^{-/-} CD8 T cells but not of TICAM-1^{-/-}, TICAM-1/IPS-1 DKO, and IRF-3/7^{-/-} mice in the i.v. setting.

Since TICAM-1 is the adaptor for TLR3 as well as cytoplasmic helicases,²⁴ we confirmed the level of cross-priming being decreased in TLR3^{-/-} mice and an expected result was obtained (Fig. S5A and B). Furthermore, in IFNAR^{-/-} mice, OVA-specific CTL induction was slightly reduced compared with that in WT mice, but higher than in TICAM-1^{-/-} mice (Fig. S5C and D). Hence, in vivo cross-




Figure 2. PolyI:C-induced tumor retardation is dependent on the TICAM-1 pathway. Antitumor effect of polyI:C on various KO mice were evaluated by using in vivo mouse tumor implant model. EG7 cells were inoculated to WT (A), TICAM-1^{-/-} (B), IPS-1^{-/-} (C) and DKO mice (D) on day 0. PBS (●), EG7 lysates (▲) or EG7 lysates + polyI:C (■) were s.c. administered around the tumor. The adjuvant therapies were started at the time indicated by the arrows and injected twice per week. Each group have 3–4 mice and error bar shows ± SEM. Data are representative of two independent experiments. **, p < 0.01

DC from WT mice when they were stimulated with OVA and polyI:C. Treatment of DC with OVA only did not induce upregulation of CD86 and CD40. Although the expression levels of CD86 and CD40 were a little less in CD8 α^+ and CD8 α^- DC from TICAM-1^{-/-} or IPS-1^{-/-} mice than those from WT mice, both CD86 and CD40 were sufficiently upregulated even in the abrogation of either one pathway in polyI:C-injected mice. The CD86 and CD40 shifts were completely abolished in DKO mice (Fig. 5A). Thus, the TICAM-1 pathway participates in both potent co-stimulation and cross-priming, while the IPS-1 pathway mainly participates only in integral co-stimulation in myeloid DC.

We next assessed in vitro proliferation of OT-1 cells. CD8 α^+ and CD8 α^- DC were prepared from PBS, polyI:C, OVA and OVA/polyI:C-treated mice, and mixed in vitro with CFSE-labeled OT-1 cells. WT, TICAM-1^{-/-} and IPS-1^{-/-} mice were used for this study. OT-1 proliferation was observed with CD8 α^+ DC but not CD8 α^- DC when OVA + polyI:C was injected (Fig. 5B). Furthermore, the OT-1 proliferation barely occurred in the mixture containing TICAM-1^{-/-} CD8 α^+ DC. Thus, OT-1 proliferation is triggered by the TICAM-1 pathway in CD8 α^+ DC. Again, IPS-1 had almost no effect on OT-1 proliferation with CD8 α^+ DC in this setting. In the mixture, IFN γ was produced in the supernatants of WT and IPS-1^{-/-} CD8 α^+ DC

but not TICAM-1^{-/-} DC by stimulation with OVA + polyI:C (Fig. 5C). No IFN γ was produced in the supernatants of CD8 α^- DC even from WT mice, which results are in parallel with those of OT-1 proliferation. In any case irrespective of tumor-bearing or not, Ag, polyI:C and the TICAM-1 pathway are mandatory for CD8 α^+ DC to cross-prime and proliferate OVA-specific CD8 T cells.

We checked the TICAM-1- or IPS-1-specific gene expressions related to Type I IFN and MHC Class I presentation using genechip and qPCR (Fig. S6). PolyI:C-mediated upregulation of *Tap1*, *Tap2* and *Tapbp* messages diminished in TICAM-1^{-/-} BMDC (Fig. S6A). The levels of these genes were hardly affected in IPS-1^{-/-} BMDC (data not shown). PolyI:C-mediated upregulation was observed with MDA5 (*Ifih1*) in CD8 α^+ and CD8 α^- DCs (Fig. S6B). Surprisingly, other factors including TLR3, TICAM-1 and MAVS messages were all downregulated in response to polyI:C in CD8 α^+ DC (Fig. S6B), for the reason as yet unknown.

Effect of TLR3-mediated IFN-inducing pathway on anti-tumor CTL induction. PolyI:C is a dsRNA analog capable of incorporating into the endosome and cytoplasm by exogenous administration in vitro.^{27,28} However, no evidence has been proposed that polyI:C is internalized into the endosome of




Figure 3. CD8 T cells in the draining LNs are activated through the TICAM-1 pathway by poly:I:C. Draining inguinal LNs were harvested from tumor-bearing mice 24 h after the last treatment. LN cells were stained with CD3 ϵ , CD8 α and CD69, and the cells gated on CD3 ϵ ⁺CD8 α ⁺ are shown (A). Spleen cells in each group of mice were stained separately, the CD8 levels in gated cells being variably distributed in FACS analyses. The average frequency of activated CD8 T cells defined by CD69 expression is shown (B). Alternatively, LN cells from the indicated mice were cultured for further 3 d in vitro and IL-2 production was measured by CBA assay (C).




Figure 4. TICAM-1 and IRF-3/7 are essential for poly:I:C-induced antigen-specific CTL expansion. WT, TICAM-1^{-/-}, IPS-1^{-/-}, TICAM-1/IPS-1 DKO and IRF-3/7^{-/-} mice were i.p. administered with the combination of OVA and poly:I:C. After 7 days, splenocytes were harvested and stained with CD8α and OVA tetramer (A). The average percentages of OVA-specific CTL are shown (B). Alternatively, splenocytes were cultured in vitro in the presence of SL8 for 8 h and IFN γ production was measured by intracellular cytokine staining (C). To assess the killing activity, in vivo CTL assay was performed. The combinations of OVA and poly:I:C were administered i.v. to each group of mice and 5 d later, cytotoxicity was measured (D). The data shown are collaborative or representative of at least three independent experiments. One-way analysis of variance (ANOVA) with Bonferroni's test was performed to analyze statistical significance. *, p < 0.05; **, p < 0.01; ***, p < 0.001.




Figure 5. TICAM-1 in CD8^α DC is more important than IPS-1 in polyI:C-induced cross-priming. OVA and polyI:C were administered i.v. and 4 h later, CD8^α and CD8^α-DC were isolated from the spleen. CD86 and CD40 expressions were determined by FACS (A). Filled gray and black line show isotype control and target expression, respectively. Alternatively, CD8^α and CD8^α-DC were co-cultured with CFSE-labeled RAG2^{-/-}/OT-1 T cells for 3 d. The cross-priming activity of each DC subset was determined with sequential dilution of CFSE (B) and IFN^γ production (C). IFN^γ was measured by CBA assay. The data shown are representative of two independent experiments. Err bar shows SD.

CD8^α DC where TLR3 is expressed in vivo. Peritoneal (PEC) Mφ and bone marrow-derived DC²² usually phagocytose polyI:C and deliver them into the endosome. In mouse CD8^α DC direct internalization of polyI:C has remain unproven. Using labeled polyI:C and anti-mouse TLR3 mAb, 11F8,²² we checked whether the exogenously-added polyI:C encountered with TLR3 in CD8^α DC in vitro. TLR3 (green) was merged with TexasRed-polyI:C 30–120 min after polyI:C stimulation in the culture (Fig. 6A). The quantities of CD8^α and CD8^α-DC where FITC-polyI:C was incorporated were determined by FACS analysis (Fig. 6B). Thus, the process by which polyI:C injected reaches the endosomal TLR3 is delineated in the CD8^α DC.

Discussion

PolyI:C is an analog of virus dsRNA, and acts as a ligand for TLR3 and RIG-I/MDA5. PolyI:C has been utilized as an adjuvant for enhancement of antitumor immunity for a long time.²⁹ However, the mechanistic background of the therapeutic potentials of polyI:C against cancer has been poorly illustrated. It induces antitumor NK activation through DC-NK cell-to-cell interaction when CD8^α DC TLR3 is stimulated in the spleen.¹¹ Besides myeloid cells, however, some tumor cell lines express TLR3 and dsRNA targeting tumor cells may affect the growth rate of tumors,³⁰ where the receptor-interacting protein (RIP) pathway is involved downstream of TICAM-1.³¹ Here we showed evidence that polyI:C injection facilitates maturation of TLR3-positive CD8^α DC (i.e., APC) to trigger CTL induction against exogenous soluble Ags including EG7 lysate or OVA. The TICAM-1 adaptor for TLR3 and IRF-3/7 are involved in the cross-presentation signal in CD8^α DC, but the molecule/mechanism downstream of TICAM-1 that governs cross-presentation remains elusive. Since most of the tumor-associated Ags (TAA) are predicted to be liberated from tumor cells




Figure 6. PolyI:C encounters TLR3 in CD8⁺ DC. CD8⁺ and CD8⁻ DC were isolated by FACS and stimulated with 20 μ g/ml TexasRed-polyI:C for 2 h. Then cells were stained with Alexa647-antiTLR3 and subjected to confocal microscopic analysis (A). Alternatively, splenic DC isolated by MACS were incubated with FITC-polyI:C for the time shown in figure and analyzed the degrees of polyI:C uptake by FACS (B). Data shown are the representative of three independent experiments.

as soluble Ags, the TICAM-1 pathway in CD8⁺ DC would be crucial for driving of tumor-specific CTL around the tumor microenvironment. In any route of polyI:C injection, this is true as shown first in this study. Although TICAM-1 is an adaptor of other cytoplasmic sensors, DDX1, DDX21 and DHX36,³² the antitumor CTL responses are merely relied on TLR3 of CD8⁺DC in this system. Taken together with previous reports,^{11,12} TICAM-1 signaling triggers not only NK activation but also CTL induction.

TLR3 and MDA5 are main sensors for dsRNA and differentially distributed in myeloid cells.^{33,34} TLR3 is limitedly expressed in myeloid, epithelial and neuronal cells,³³ whereas MDA5 is ubiquitously expressed including non-myeloid stromal cells.³³ Several reports suggested that i.v. injection of polyI:C predominantly stimulate the stromal cells which express IFNAR,²⁶ thereby robust type I IFN are liberated from these cells to be a systemic response including cytokinemia and endotoxin-like shock.^{35,36} Both TLR3 and MDA5 link to the IRF-3/7-activating kinases leading to the production of IFN α/β .^{37,38} Once IFN α/β are released, IFNAR senses it to amplify the Type I IFN production,³⁹ and reportedly this amplification pathway involves cross-priming of CD8 T cells in viral infection.¹⁸ Tumor progression or metastasis can be suppressed through the IFNAR pathway.⁴⁰ These scenarios may be right depending on the conditions employed. Our message is related to what signal pathway is fundamentally required for induction of antitumor CTL in DC. The CTL response is almost completely abrogated in TICAM-1^{-/-} and IRF-3/7^{-/-} mice, but largely remains in IPS-1^{-/-} and IFNAR^{-/-} mice when Ag and polyI:C are extrinsically administered. The results are reproducible in some other tumor-implant models (data not shown), and even in IFNAR^{-/-} mice, TICAM-1-specific genes are upregulated to confer tumor cytotoxicity (Fig. S6, Azuma et al., unpublished data). In addition, the upregulation of these genes is independent of IPS-1 knockout in DC. Our results infer that the primary sensing of dsRNA in CD8⁺ DC is competent to induce cross-presentation, which minimally involves the IPS-1 or IFNAR amplification pathway, at least at a low dose of polyI:C. Yet, subsequent induction of Type I IFN via the IFNAR may further amplify the cross-priming.^{18,41} Further studies are needed as to which of the TICAM-1-inducible genes link to the cross-presentation in CD8⁺ DC.

The main focus of this study was to identify the pathway for transversion of immature DC to the CTL-driving phenotype by co-administration of polyI:C with soluble Ag. The IPS-1 pathway, although barely participates in antitumor CTL driving, can upregulate CD40/CD86 co-stimulators on the membranes of splenic CD8⁺ and CD8⁻ DC in response to polyI:C, suggesting that MDA5 does function in the cytoplasm of splenic CD8⁺ and CD8⁻ DC to sense polyI:C. However, effective CTL induction happens only in CD8⁺ DC when stimulated with polyI:C. CD8⁺ DC express TLR3 but CD8⁻ DC do not, and CD8⁺ DC with no TLR3 fail to induce CTL, suggesting that integral co-stimulation by MDA5/IPS-1 is insufficient for DC to induce cross-priming of CD8 T cells: antitumor CTL are not induced until the TICAM-1 signal is provided in DC. At least, sole effect of the IPS-1 pathway and upregulation of co-stimulators on CD8⁺ DC is limited for cross-priming and induction of antitumor CTL, which result partly reflects those in a previous report where IPS-1 and TICAM-1 harbor a similar potential for CD8 T cell proliferation when

polyI:C (Alum-containing) is employed as an adjuvant for CD8 α ⁺ DC to test proliferation of anti-OVA CTL.²¹

A question is why TICAM-1 is dominant to IPS-1 for response to exogenously-added polyI:C in CD8 α ⁺ DC. The answer is rooted in the difference of functional behavior between BMDC and CD8 α ⁺ DC. TLR3 levels are variable depending upon subsets of DC,²² which affects DC subset-specific induction of cellular immune response. The high TLR3 expression (partly surface-expressed) is situated in CD8 α ⁺ DC before polyI:C stimulation, which is distinct from the properties of F4/80⁺ Mf and presumably BMDC of low TLR3 expression. The polyI:C-uptake machinery¹⁵ appears to efficiently work in concert with the TLR3/TICAM-1 pathway in CD8 α ⁺ DC and this tendency is diminished when CD8 α ⁺ DC are pretreated with Alum + polyI:C.²¹ Furthermore, there are functional discrepancies between CD8 α ⁺ splenic DC and GM-CSF-induced BMDC, which appears to reflect the difference of their TLR3 levels.²² These results on CD8 α ⁺ DC encourage us to develop dsRNA adjuvant immunotherapy supporting TAA soluble vaccines for cancer applicable to humans, which possess the counterpart of CD8 α ⁺ DC.

There are two modes of dsRNA-mediated DC maturation, intrinsic and extrinsic modes that are governed by the IPS-1 and TICAM-1 pathways, respectively.^{9,34} It is important to elucidate the in vivo qualitative difference in the two pathways in tumor-loading mice. TLR3⁺ DC/Mf are responsible for CTL driving via an extrinsic route in viral infection.³⁴ Previous data suggested that dsRNA in infectious cell debris, rather than viral dsRNA produced in the cytoplasm of Ag-presenting cells or autophagosome formation, contribute to fine tuning of DC maturation through extrinsic dsRNA recognition.¹⁶ It is reported that dsRNA-containing debris are generated secondary to infection-mediated cell death,⁴¹ and DC phagocytose by-stander dead cells. Likewise, soluble tumor Ags released from tumor cells usually are extrinsically taken up by APC in patients with cancer.⁴² If CTL are successfully induced in therapeutic biotherapy targeted against cancer cells, this extrinsic TICAM-1 pathway must be involved in the therapeutic process.

Cross-presentation occurs in a TAP-dependent⁴³ and -independent fashions.^{44,45} The peptides are transported by TAP into the endoplasmic reticulum (ER) and loaded onto MHC Class I for presentation at the cell surface. ER and phagosome might fuse each other for accelerating cross-presentation.⁴⁶ Another possibility is that cross-presentation occurs in early endosomes where TLR3 resides. This early endosome cross-presentation does not always depend on TAP⁴²⁻⁴⁴ but requires TLR stimulation.³⁴ TLR4/MyD88 pathway is involved in the TAP-dependent early endosome model,⁴³ where recruitment of TAP to the early endosomes is an essential step for the cross-presentation of soluble Ag. These models together with our genechip analysis of polyI:C-stimulated BMDC suggested that some ER-associated proteins are upregulated in BMDC by polyI:C-TICAM-1 pathway. The results infer that the TLR3/TICAM-1 rather than the TLR4/MyD88 pathway more crucially participates in cross-presentation in response to dsRNA or viral stimuli and facilitates raising CTL antitumor immunity in APC.

Although multiple RNA sensors couple with TICAM-1 and signal to activate the Type I IFN-inducing pathway,²⁵ at least TLR3 in the CD8 α ⁺ DC are critical in CTL driving. CD8 α ⁺ DC are a high TLR3 expresser, while BMDC express TLR3 with only low levels.²² CD8 α ⁻ DC do not express it.²² The Ag presentation and TLR3 levels in CD8 α ⁺ DC appear reciprocally correlated with the phagocytosing ability of DC. Although the TLR3 mRNA level is downregulated secondary to polyI:C response after maturation, this may not be related to the CD8 α ⁻ DC functions. Yet, polyI:C might interact with other cytoplasmic sensors for DC maturation,^{32,47}

The route of administration and delivery methods may be important for culminate the polyI:C adjuvant function. The toxic problem has not overcome in the adjuvant therapy using polyI:C^{35,36} and this is a critical matter for clinical introduction of dsRNA reagents to immunotherapy. The most problematic is the life-threatening shock induced by polyI:C. Recent advance of polyI:C study suggests that PEI-jet helps efficient uptake of polyI:C into peritoneal macrophages.⁴⁸ LC (poly-L-lysine and methyl-cellulose) has been used as a preservative to reduce the toxic effect of polyI:C.⁴⁹ Nanotechnological delivery of polyI:C results in efficient tumor regression.⁵⁰ There are many subsets of DC that can be defined by surface markers, and selecting an appropriate administration route can target a specific DC subset. The route for s.c. administration usually mature dermal/epidermal DC or Langerhans cells.^{51,52} Some DC subsets with unique properties specialized to CTL induction would work in association with the route of polyI:C administration. Attempting to develop more harmless and efficient dsRNA derivatives will benefit for establishing human adjuvant immunotherapy for cancer.

Materials and Methods

Mice. TICAM-1^{-/-} and IPS-1^{-/-} mice were made in our laboratory and backcrossed more than eight times to adapt C57BL/6 background.¹² IRF-3/7^{-/-} and IFNAR^{-/-} mice were kindly provided by T. Taniguchi (University of Tokyo, Tokyo, Japan). TLR3^{-/-} mice were kindly provided by S. Akira (Osaka University, Osaka, Japan). Rag2^{-/-} and OT-1 mice were kindly provided from Drs N. Ishii (Tohoku University, Sendai, Japan). Rag2^{-/-}/OT-1 mice were bred in our laboratory. All mice were maintained under specific pathogen-free conditions in the animal facility of the Hokkaido University Graduate School of Medicine. Animal experiments were performed according to the guidelines set by the animal safety center, Hokkaido University, Japan.

Cells. EG7 and C1498 cells were purchased from ATCC and cultured in RPMI1640/10% FCS/55 μ M 2-ME/1 mM sodium pyruvate and RPMI1640/10% FCS/25 ng/ml 2-ME, respectively. Mouse splenocytes, OT-1 T cell, CD8 α ⁺ DC and CD8 α ⁻ DC were harvested from the spleen and cultured in RPMI1640/10% FCS/55 μ M 2-ME/10 mM HEPES.⁴¹ B16D8 cells were cultured in RPMI/10% FCS as described previously.¹²

Reagents and antibodies. Ovalbumin (OVA) and polyI:C (polyI:C) were purchased from SIGMA and Amersham Biosciences, respectively. OVA₂₅₇₋₂₆₄ peptide (SIINFEKL: SL8)

and OVA (H2K^b-SL8) Tetramer were from MBL. Following Abs were purchased: anti-CD3 ϵ (145-2C11), anti-CD8 β (53-6.7), anti-CD11c (N418), anti-CD16/32 (93), anti-CD69 (H1.2F3) and anti-IFN γ (XMG1.2) Abs from BioLegend, anti-B220 (RA3-6B2), anti-CD4 (L3T4), anti-CD40 (1C10), anti-CD86 (GL1), and anti-MHC I-SL8 (25-D1.16) Abs from eBiosciences, anti-TCR-V β 5.1/5.2 Ab and ViaProbe from BD Biosciences. The Rat anti-mouse TLR3 mAb (11F8) was kindly provided by David M. Segal (National Institute of Health, Bethesda, MD). To rule out LPS contamination, we treated OVA or other reagents with 200 μ g/ml of Polymixin B for 30 min at 37°C before use. Texas Red- or FITC-labeled poly(I:C) was prepared using the 5' EndTagTM Nucleic Acid Labeling System (Vector Laboratories) according to the manufacturers instructions.

Tumor challenge and poly I:C therapy. Mice were shaved at the back and s.c. injected with 200 μ l of 2×10^6 syngenic EG7 cells in PBS. Tumor volumes were measured at regular intervals by using a caliper. Tumor volume was calculated by using the formula: Tumor volume (cm³) = (long diameter) \times (short diameter)² \times 0.4. A volume of 50 μ l of a mixture consisting of the lysate of 2×10^5 EG7 cells with or without 50 μ g of poly I:C (polyI:C) was s.c. injected around the tumor. We added no other emulsified reagent for immunization since we want to rule out the conditional effect of the Ag/polyI:C. The treatments were started when the average of tumor volumes reached at 0.4–0.8 cm³ and performed twice per week. EG7 lysate were prepared by three times freeze/thaw cycles (-140°C/37°C) in PBS, with removal of cell debris by centrifugation at 6,000 g for 10 min.⁵³ To deplete CD8 T cells, mice were i.p. injected with hybridoma ascites of anti-CD8 β mAb. The dose of antibody and the treatment regimens were determined in preliminary studies by using the same lots of antibody used for the experiments. Depletion of the desired cell populations by this treatment was confirmed by FACS for the entire duration of the study.

Evaluation of T cell activity in tumor-bearing mice. Draining inguinal LN cells were harvested from tumor-bearing mice after 24 h from the last polyI:C treatment. The activity of T cells was evaluated by CD69 expression and IL-2/IFN γ production. These cells were stained with FITC-CD8 α , PE-CD69, PerCP/Cy5.5-7AAD and APC-CD3 ϵ . To check cytokine production, LN cells were cultured for 3 d in vitro in the presence or absence of EG7 lysates and IL-2 and IFN γ productions were determined by Cytokine Beads Array (CBA) assay (BD). To assess the cytotoxic activity of CTL, standard ⁵¹Cr release assay was performed. For CTL expansion, 2.5×10^6 LN cells were co-cultured with 1.25×10^5 mitomycin C-treated EG7 cells in the presence of 10 U/ml IL-2 for 5 d. Then, LN cells were incubated with ⁵¹Cr-labeled EG7 or C1498 cells for 4 h and determined cytotoxic activity. The cell-specific cytotoxicity was calculated with subtracting the cytotoxicity for C1498 from for EG7 cells.

Antigen-specific T cell expansion in vivo. Mice were i.p. immunized with 1 mg of OVA and 150 μ g of poly I:C. After 7 d, spleens were homogenized and stained with FITC-CD8 α and PE-OVA Tetramer for detecting OVA-specific CD8 T cell

populations. For intracellular cytokine detection, splenocytes were cultured with or without 100 nM OVA peptide (SIINFEKL; SL8) for 8 h and 10 μ g/ml of Brefeldin A (Sigma-Aldrich) was added to the culture in the last 4 h. Then cells were stained with PE-anti-CD8 α and fixed/permeabilized with Cytofix/Cytoperm (BD Biosciences) according to manufacturer's instruction. Then, fixed/permeabilized cells were further stained with APC-anti-IFN γ . Stained cells were analyzed with FACSCalibur (BD Biosciences) and FlowJo software (Tree Star).

In vivo CTL assay. The in vivo CTL assay was performed as described.⁵⁴ In brief, WT, TICAM-1^{-/-}, MAVS^{-/-} and IRF-3/7^{-/-} mice were i.v. administered with PBS, 10 μ g of OVA or OVA with 50 μ g of polyI:C. After 5 d, 2×10^7 target cells (see below) were i.v. injected to other irrelevant mice and 8 h later, the OVA-specific cytotoxicity was measured by FACSCalibur. Target cells were 1:1 mixture of 2 μ M SL8-pulsed, 5 μ M CFSE-labeled splenocytes and SL8-unpulsed, 0.5 μ M CFSE-labeled splenocytes. OVA-specific cytotoxicity was calculated with a formula: $\{1 - (\text{Primed } [\text{CFSE}^{\text{high}}(\%)/\text{CFSE}^{\text{low}}(\%)] / \text{Unprimed } [\text{CFSE}^{\text{high}}(\%)/\text{CFSE}^{\text{low}}(\%)])\} \times 100$.

DC preparation. DCs were prepared from spleens of mice, as described previously.⁵⁵ In brief, collagenase-digested spleen cells were treated with ACK buffer and then washed with PBS twice. Then splenocytes were positively isolated with anti-CD11c MicroBeads. CD11c⁺ cells were acquired routinely about $\geq 80\%$ purity. Further, to highly purify CD8 α^+ and CD8 α^- DCs, spleen DC were stained with FITC-CD8 α , PE-B220, PE/Cy7-CD11c and PerCP5.5-7AAD. CD8 α^+ or CD8 α^- CD11c⁺B220⁻ DCs were purified on FACSARIAII (BD). The purity of the cells was $\geq 98\%$.

OT-1 proliferation assay. Ten micrograms of OVA with or without 50 μ g of polyI:C were i.v. injected to WT, TICAM-1^{-/-}, IPS-1^{-/-} and DKO mice. After 4 h, CD8 α^+ or CD8 α^- DC were purified from the spleen. 2.5×10^4 CD8 α^+ or CD8 α^- DC were co-cultured with 5×10^4 1 μ M CFSE-labeled Rag2^{-/-}/OT-1 T cells for 3 d in 96-well round bottom plate. These cells were stained with PE-anti-TCR-V β 5.1,5.2 and APC-anti-CD3 ϵ and T cell proliferation was analyzed by CFSE dilution using FACSCalibur. Additionally, IFN γ in the culture supernatant was measured by CBA assay.

Statistical analysis. P-values were calculated with one-way analysis of variance (ANOVA) with Bonferroni's test. Error bars represent the SD or SEM between samples.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgment

We are grateful to Drs. T. Taniguchi (University Tokyo, Tokyo), N. Ishii (Tohoku University, Sendai) and D.M. Segal (NCI, Bethesda) for providing us with IRF-3/7^{-/-} mice, OT-1 mice and anti-mouse TLR3 mAb, respectively. Invaluable discussions about the peptide vaccine therapy with Dr. N. Satoh (Sapporo Medical

University, Sapporo) are gratefully acknowledged. We thank Drs H. Takaki, J. Kasamatsu, H.H. Aly, and H. Shime in our lab for their critical comments on this study.

This work was supported in part by Grants-in-Aid from the Ministry of Education, Science, and Culture (Specified Project for Advanced Research, MEXT) and the Ministry of Health, Labor, and Welfare of Japan, and by the Takeda and the Waxmann

Foundations. Financial supports by a MEXT Grant-in-Project “The Carcinogenic Spiral” is gratefully acknowledged.

Supplemental Materials

Supplemental materials may be found here:
<http://www.landesbioscience.com/journals/oncoimmunology/article/19893/>

References

- Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. *Science* 2010; 327:291-5; PMID:20075244; <http://dx.doi.org/10.1126/science.1183021>
- Seya T, Shime H, Ebihara T, Oshiumi H, Matsumoto M. Pattern recognition receptors of innate immunity and their application to tumor immunotherapy. *Cancer Sci* 2010; 101:313-20; PMID:20059475; <http://dx.doi.org/10.1111/j.1349-7006.2009.01442.x>
- Akira S. Toll-like receptor signaling. *J Biol Chem* 2003; 278:38105-8; PMID:12893815; <http://dx.doi.org/10.1074/jbc.R300028200>
- Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. *Int Immunol* 2009; 21:317-37; PMID:19246554; <http://dx.doi.org/10.1093/intimm/dxp017>
- Longman RS, Braun D, Pellegrini S, Rice CM, Darnell RB, Albert ML. Dendritic-cell maturation alters intracellular signaling networks, enabling differential effects of IFN-alpha/beta on antigen cross-presentation. *Blood* 2007; 109:1113-22; PMID:17018853; <http://dx.doi.org/10.1182/blood-2006-05-023465>
- Shinohara ML, Kim JH, Garcia VA, Cantor H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. *Immunity* 2008; 29:68-78; PMID:18619869; <http://dx.doi.org/10.1016/j.immuni.2008.05.008>
- Diebold SS. Recognition of viral single-stranded RNA by Toll-like receptors. *Adv Drug Deliv Rev* 2008; 60:813-23; PMID:18241955; <http://dx.doi.org/10.1016/j.addr.2007.11.004>
- Matsumoto M, Oshiumi H, Seya T. Antiviral responses induced by the TLR3 pathway. *Rev Med Virol* 2011. Epub ahead of print. PMID:21312311; <http://dx.doi.org/10.1002/rmv.680>
- Yoneyama M, Fujita T. RIG-I family RNA helicases: cytoplasmic sensor for antiviral innate immunity. *Cytokine Growth Factor Rev* 2007; 18:545-51; PMID:17683970; <http://dx.doi.org/10.1016/j.cytogfr.2007.06.023>
- Seya T, Matsumoto M. The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer. *Cancer Immunol Immunother* 2009; 58:1175-84; PMID:19184005; <http://dx.doi.org/10.1007/s00262-008-0652-9>
- Akazawa T, Ebihara T, Okuno M, Okuda Y, Shingai M, Tsujimura K, et al. Antitumor NK activation induced by the Toll-like receptor 3-TRIF (TRIF) pathway in myeloid dendritic cells. *Proc Natl Acad Sci U S A* 2007; 104:252-7; PMID:17190817; <http://dx.doi.org/10.1073/pnas.0605978104>
- Ebihara T, Azuma M, Oshiumi H, Kasamatsu J, Iwabuchi K, Matsumoto K, et al. Identification of a poly(I:C)-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation. *J Exp Med* 2010; 207:2675-87; PMID:21059856; <http://dx.doi.org/10.1084/jem.20091573>
- Perrot I, Deauvieu F, Massacrier C, Hughes N, Garrone P, Durand I, et al. TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA. *J Immunol* 2010; 185:2080-8; PMID:20639488; <http://dx.doi.org/10.4049/jimmunol.1000532>
- Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. *J Exp Med* 1976; 143:1283-8; PMID:1083422; <http://dx.doi.org/10.1084/jem.143.5.1283>
- Datta SK, Redecke V, Prillman KR, Takabayashi K, Corr M, Tallant T, et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. *J Immunol* 2003; 170:4102-10; PMID:12682240
- Schulz O, Diebold SS, Chen M, Nöslund TI, Nolte MA, Alexopoulou L, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. *Nature* 2005; 433:887-92; PMID:15711573; <http://dx.doi.org/10.1038/nature03326>
- Kono H, Rock KL. How dying cells alert the immune system to danger. *Nat Rev Immunol* 2008; 8:279-89; PMID:18340345; <http://dx.doi.org/10.1038/nri2215>
- Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. *Nat Immunol* 2003; 4:1009-15; PMID:14502286; <http://dx.doi.org/10.1038/ni978>
- Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. *J Exp Med* 1997; 186:65-70; PMID:9206998; <http://dx.doi.org/10.1084/jem.186.1.65>
- Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S. Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. *J Exp Med* 2007; 204:2641-53; PMID:17923500; <http://dx.doi.org/10.1084/jem.20070458>
- Kumar H, Koyama S, Ishii KJ, Kawai T, Akira S. Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. *J Immunol* 2008; 180:683-7; PMID:18178804
- Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, Goldsmith PK, et al. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. *J Immunol* 2011; 186:2422-9; PMID:21242525; <http://dx.doi.org/10.4049/jimmunol.1002845>
- Wang Y, Cella M, Gilfillan S, Colonna M. Cutting edge: polyinosinic:polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells. *J Immunol* 2010; 184:2751-5; PMID:20164430; <http://dx.doi.org/10.4049/jimmunol.0903201>
- Carbone FR, Bevan MJ. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization. *J Exp Med* 1989; 169:603-12; PMID:2784478; <http://dx.doi.org/10.1084/jem.169.3.603>
- Asano J, Tada H, Onai N, Sato T, Horie Y, Fujimoto Y, et al. Nucleotide oligomerization domain-like receptor signaling enhances dendritic cell-mediated cross-priming in vivo. *J Immunol* 2010; 184:736-45; PMID:20008287; <http://dx.doi.org/10.4049/jimmunol.0900726>
- McCartney S, Vermi W, Gilfillan S, Cella M, Murphy TL, Schreiber RD, et al. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. *J Exp Med* 2009; 206:2967-76; PMID:19995959; <http://dx.doi.org/10.1084/jem.20091181>
- Watanabe A, Tatsumatsu M, Saeki K, Shibata S, Shime H, Yoshimura A, et al. Rafilin is involved in the nucleocapture complex to induce poly(I:C)-mediated TLR3 activation. *J Biol Chem* 2011; 286:10702-11; PMID:21266579; <http://dx.doi.org/10.1074/jbc.M110.185793>
- Itoh K, Watanabe A, Funami K, Seya T, Matsumoto M. The clathrin-mediated endocytic pathway participates in dsRNA-induced IFN-beta production. *J Immunol* 2008; 181:5522-9; PMID:18832709
- Talmadge JE, Adams J, Phillips H, Collins M, Lenz B, Schneider M, et al. Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose. *Cancer Res* 1985; 45:1058-65; PMID:3155990
- Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, et al. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. *Cancer Res* 2010; 70:490-500; PMID:20068181; <http://dx.doi.org/10.1158/0008-5472.CAN-09-1890>
- Kaiser WJ, Offermann MK. Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. *J Immunol* 2005; 174:4942-52; PMID:15814722
- Zhang Z, Kim T, Bao M, Facchinetti V, Jung SY, Ghaffari AA, et al. DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. *Immunity* 2011; 34:866-78; PMID:21703541; <http://dx.doi.org/10.1016/j.immuni.2011.03.027>
- Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. *Proc Natl Acad Sci U S A* 2006; 103:8459-64; PMID:16714379; <http://dx.doi.org/10.1073/pnas.0603082103>
- Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). *Adv Drug Deliv Rev* 2008; 60:805-12; PMID:18262679; <http://dx.doi.org/10.1016/j.addr.2007.11.005>

35. Absher M, Stinebring WR. Toxic properties of a synthetic double-stranded RNA. Endotoxin-like properties of poly I. poly C, an interferon stimulator. *Nature* 1969; 223:715-7; PMID:5805520; <http://dx.doi.org/10.1038/223715a0>
36. Berry LJ, Smythe DS, Colwell LS, Schoengold RJ, Actor P. Comparison of the effects of a synthetic polyribonucleotide with the effects of endotoxin on selected host responses. *Infect Immun* 1971; 3:444-8; PMID:16557994
37. Sasai M, Shingai M, Funami K, Yoneyama M, Fujita T, Matsumoto M, et al. NAK-associated protein 1 participates in both the TLR3 and the cytoplasmic pathways in type I IFN induction. *J Immunol* 2006; 177:8676-83; PMID:17142768
38. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. *Nature* 2008; 455:674-8; PMID:18724357; <http://dx.doi.org/10.1038/nature07317>
39. Taniguchi T, Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. *Nat Rev Mol Cell Biol* 2001; 2:378-86; PMID:11331912; <http://dx.doi.org/10.1038/35073080>
40. Ogasawara S, Yano H, Momosaki S, Akiba J, Nishida N, Kojiro S, et al. Growth inhibitory effects of IFN-beta on human liver cancer cells in vitro and in vivo. *J Interferon Cytokine Res* 2007; 27:507-16; PMID:17572015; <http://dx.doi.org/10.1089/jir.2007.0183>
41. Ebihara T, Shingai M, Matsumoto M, Wakita T, Seya T. Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells. *Hepatology* 2008; 48:48-58; PMID:18537195; <http://dx.doi.org/10.1002/hep.22337>
42. Chaput N, Conforti R, Viaud S, Spatz A, Zitvogel L. The Janus face of dendritic cells in cancer. *Oncogene* 2008; 27:5920-31; PMID:18836473; <http://dx.doi.org/10.1038/onc.2008.270>
43. Burgdorf S, Schölz C, Kautz A, Tampé R, Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. *Nat Immunol* 2008; 9:558-66; PMID:18376402; <http://dx.doi.org/10.1038/ni.1601>
44. Shen L, Sigal LJ, Boes M, Rock KL. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. *Immunity* 2004; 21:155-65; PMID:15308097; <http://dx.doi.org/10.1016/j.immuni.2004.07.004>
45. Kurotaki T, Tamura Y, Ueda G, Oura J, Kutomi G, Hirohashi Y, et al. Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. *J Immunol* 2007; 179:1803-13; PMID:17641047
46. Gagnon E, Dudos S, Rondeau C, Chevet E, Cameron PH, Steele-Mortimer O, et al. Endoplasmic reticulum-mediated phagocytosis is a mechanism of entry into macrophages. *Cell* 2002; 110:119-31; PMID:12151002; [http://dx.doi.org/10.1016/S0092-8674\(02\)00797-3](http://dx.doi.org/10.1016/S0092-8674(02)00797-3)
47. Samuel CE. Antiviral actions of interferons. *Clin Microbiol Rev* 2001; 14:778-809; PMID:11585785; <http://dx.doi.org/10.1128/CMR.14.4.778-809.2001>
48. Wu CY, Yang HY, Monie A, Ma B, Tsai HH, Wu TC, et al. Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors. *Cancer Immunol Immunother* 2011; 60:1085-96; PMID:21526359; <http://dx.doi.org/10.1007/s00262-011-1013-7>
49. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. *J Exp Med* 2009; 206:1589-602; PMID:19564349; <http://dx.doi.org/10.1084/jem.20090247>
50. Kitano S, Kageyama S, Nagata Y, Miyahara Y, Hiasa A, Naota H, et al. HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. *Clin Cancer Res* 2006; 12:7397-405; PMID:17189412; <http://dx.doi.org/10.1158/1078-0432.CCR-06-1546>
51. Kushwah R, Hu J. Complexity of dendritic cell subsets and their function in the host immune system. *Immunology* 2011; 133:409-19; PMID:21627652; <http://dx.doi.org/10.1111/j.1365-2567.2011.03457.x>
52. Asano K, Nabeyama A, Miyake Y, Qiu CH, Kurita A, Tomura M, et al. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. *Immunity* 2011; 34:85-95; PMID:21194983; <http://dx.doi.org/10.1016/j.immuni.2010.12.011>
53. Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. *Cancer Immunol Immunother* 2004; 53:963-77; PMID:15146294; <http://dx.doi.org/10.1007/s00262-004-0542-8>
54. Durand V, Wong SY, Tough DF, Le Bon A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN- α/β . *Immunol Cell Biol* 2004; 82:596-602; PMID:15550117; <http://dx.doi.org/10.1111/j.0818-9641.2004.01285.x>
55. Yamazaki S, Okada K, Maruyama A, Matsumoto M, Yagita H, Seya T. TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. *PLoS One* 2011; 6:e18833; PMID:21533081; <http://dx.doi.org/10.1371/journal.pone.0018833>